

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information  
**Olerup SSP® HLA-A\*26**

<b>Product number:</b>	<b>101.424-12 – including <i>Taq</i> polymerase</b> <b>101.424-12u – without <i>Taq</i> polymerase</b>
<b>Lot number:</b>	<b>6G1</b>
<b>Expiry date:</b>	<b>2021-03-01</b>
<b>Number of tests:</b>	<b>12</b>
<b>Number of wells per test:</b>	<b>47+1</b>
<b>Storage - pre-aliquoted primers:</b>	<b>dark at -20°C</b>
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

**This Product Description is only valid for Lot No. 6G1.**

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate

**CHANGES COMPARED TO THE PREVIOUS OLERUP SSP®  
HLA-A\*26 LOT (1F3)**

The HLA-A\*26 kit is updated for new alleles to enable separation of:

- Null and Alternatively expressed alleles
- The product documentation has been updated for new alleles of IMGT 3.32.0

The format of the Worksheet has been changed.

The HLA-A\*26 specificity and interpretation tables have been updated for the HLA-B alleles described since the previous *Olerup SSP®* HLA-A\*26 lot was made (**Lot No.1F3**).

The primers of the wells detailed below have been exchanged, added or modified compared to the previous lot.

Well	5'-primer	3'-primer	rationale
2	-	Added	3'-primer added for the A*26:137 allele.
27	Added	-	5'-primer added for the A*26:145N allele.
38	Added	-	5'-primer added for the A*26:145N allele.

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

Well **48** contains Negative Control primer pairs, that will amplify more than 95% of the *Olerup* SSP<sup>®</sup> HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.  
The PCR product generated by the positive control primer pair is 430 base pairs.

Length of PCR product	105	200	105	80	75	80	85
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>	<b>36</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-TAC <sup>3'</sup>
							<b>36</b>
							5'-TAT <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>	<b>47</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ACA <sup>3'</sup>
							<b>48</b>
							5'-gCA <sup>3'</sup>
							<b>48</b>
							5'-gCC <sup>3'</sup>
							<b>52</b>
							5'-TgT <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>				
<b>DRB1</b>				<b>+</b>	<b>+</b>		
<b>DRB3</b>				<b>+</b>	<b>+</b>		
<b>DRB5</b>				<b>+</b>			
<b>DQB1</b>					<b>+</b>		
<b>DPB1</b>						<b>+</b>	
<b>DQA1</b>							<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-A\*26 SSP subtyping

#### CONTENT

The primer set contains 5'- and 3'-primers for identifying the A\*26:01 to A\*26:149 alleles.

#### PLATE LAYOUT

Each test consists of 48 PCR reactions in a 48 well cut PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	32
33	34	35	36	37	38	39	40
41	42	43	44	45	46	47	NC

The 48 well PCR plate is marked with ‘HLA-A\*26’ in silver/gray ink.

Well No. 1 is marked with the Lot Number ‘6G1’.

Wells 1 to 47 – HLA-A\*26 high resolution primers.

Well 48 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded. The PCR plates are covered with a PCR-compatible foil.

**Please note:** When removing each 48 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

#### INTERPRETATION

Due to the sharing of sequence motifs between HLA-A alleles non-HLA-A\*26 alleles will be amplified by some primer mixes. For further details see Specificity Table.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-A\*26 alleles, i.e. **A\*26:01 to A\*26:149**, recognized by the HLA Nomenclature Committee in April 2018 will be amplified by the primers in the HLA-A\*26 subtyping kit<sup>1,2</sup>.

The HLA-A\*26 kit enables separation of the confirmed HLA-A\*26 alleles as listed in the IMGT/HLA database 3.26.0. An HLA allele is listed as confirmed by IMGT/HLA if it has been sequenced by more than a single laboratory or from multiple sources. Current allele confirmation status for HLA-A\*26 alleles is listed below.

The HLA-A\*26 kit also enables identification of null and alternatively expressed alleles.

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

**Lot No.: 6G1**

**Lot-specific information**

The following HLA-A\*26 alleles can be distinguished by the different sizes of the HLA-specific PCR product:

Alleles	Primer mix	Alleles	Primer mix
A*26:17, 26:106	13	A*26:46, 26:53	33
A*26:23, 26:27	20	A*26:54-26:55	36
A*26:24, 26:41	21	A*26:59, 26:69	35
A*26:25N, 26:38	22	A*26:62-26:63	39
A*26:36, 26:116	28	A*26:68, 26:130	44
A*26:43:01, 26:61	32	A*26:103, 26:107N	43

<sup>1</sup>HLA-A alleles listed on the IMGT/HLA web page 2018-April-16, release 3.32.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

**ALLELE CONFIRMATION STATUS**

Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>	Allele	Status <sup>1</sup>
A*26:01:01:01	Confirmed	A*26:07:02	Confirmed	A*26:57	Unconfirmed	A*26:107N	Unconfirmed
A*26:01:01:02	Confirmed	A*26:08	Confirmed	A*26:58	Confirmed	A*26:108	Unconfirmed
A*26:01:01:03N	Unconfirmed	A*26:09	Unconfirmed	A*26:59	Confirmed	A*26:109	Unconfirmed
A*26:01:01:04	Unconfirmed	A*26:10	Unconfirmed	A*26:60N	Unconfirmed	A*26:110	Unconfirmed
A*26:01:02	Confirmed	A*26:11N	Unconfirmed	A*26:61	Unconfirmed	A*26:111	Unconfirmed
A*26:01:03	Unconfirmed	A*26:12	Confirmed	A*26:62	Confirmed	A*26:112	Confirmed
A*26:01:04	Confirmed	A*26:13	Unconfirmed	A*26:63	Confirmed	A*26:113	Unconfirmed
A*26:01:05	Unconfirmed	A*26:14	Confirmed	A*26:64	Unconfirmed	A*26:114	Unconfirmed
A*26:01:06	Confirmed	A*26:15	Confirmed	A*26:65	Confirmed	A*26:115	Confirmed
A*26:01:07	Unconfirmed	A*26:16	Unconfirmed	A*26:66	Unconfirmed	A*26:116	Confirmed
A*26:01:08	Unconfirmed	A*26:17	Confirmed	A*26:67	Unconfirmed	A*26:117	Unconfirmed
A*26:01:09	Unconfirmed	A*26:18	Confirmed	A*26:68	Confirmed	A*26:118	Unconfirmed
A*26:01:10	Unconfirmed	A*26:19	Unconfirmed	A*26:69	Confirmed	A*26:119	Unconfirmed
A*26:01:11	Confirmed	A*26:20	Confirmed	A*26:70	Unconfirmed	A*26:120	Unconfirmed
A*26:01:12	Unconfirmed	A*26:21	Unconfirmed	A*26:71N	Confirmed	A*26:121	Unconfirmed
A*26:01:13	Unconfirmed	A*26:22	Unconfirmed	A*26:72	Confirmed	A*26:122	Unconfirmed
A*26:01:14	Unconfirmed	A*26:23	Unconfirmed	A*26:73	Confirmed	A*26:123	Unconfirmed
A*26:01:15	Confirmed	A*26:24	Unconfirmed	A*26:74	Confirmed	A*26:124	Unconfirmed
A*26:01:16	Unconfirmed	A*26:25N	Unconfirmed	A*26:75	Confirmed	A*26:125	Unconfirmed
A*26:01:17	Confirmed	A*26:26	Unconfirmed	A*26:76	Unconfirmed	A*26:126	Unconfirmed
A*26:01:18	Confirmed	A*26:27	Confirmed	A*26:77	Unconfirmed	A*26:127N	Unconfirmed
A*26:01:19	Confirmed	A*26:28	Confirmed	A*26:78	Unconfirmed	A*26:128	Unconfirmed
A*26:01:20	Confirmed	A*26:29	Unconfirmed	A*26:79	Unconfirmed	A*26:129	Unconfirmed
A*26:01:21	Unconfirmed	A*26:30	Unconfirmed	A*26:80	Unconfirmed	A*26:130	Confirmed
A*26:01:22	Unconfirmed	A*26:31	Confirmed	A*26:81	Unconfirmed	A*26:131	Unconfirmed
A*26:01:23	Confirmed	A*26:32	Unconfirmed	A*26:82	Unconfirmed	A*26:132	Unconfirmed
A*26:01:24	Unconfirmed	A*26:33	Unconfirmed	A*26:83	Unconfirmed		
A*26:01:25	Unconfirmed	A*26:34	Unconfirmed	A*26:84	Unconfirmed		
A*26:01:26	Unconfirmed	A*26:35	Unconfirmed	A*26:85	Unconfirmed		
A*26:01:27	Unconfirmed	A*26:36	Confirmed	A*26:86	Unconfirmed		
A*26:01:28	Unconfirmed	A*26:37	Unconfirmed	A*26:87	Unconfirmed		
A*26:01:29	Unconfirmed	A*26:38	Confirmed	A*26:88	Unconfirmed		
A*26:01:30	Unconfirmed	A*26:39	Confirmed	A*26:89	Unconfirmed		
A*26:01:31	Unconfirmed	A*26:40	Unconfirmed	A*26:90	Unconfirmed		
A*26:01:32	Unconfirmed	A*26:41	Unconfirmed	A*26:91	Unconfirmed		
A*26:01:33	Unconfirmed	A*26:42	Confirmed	A*26:92	Unconfirmed		
A*26:01:34	Unconfirmed	A*26:43:01	Unconfirmed	A*26:93	Unconfirmed		
A*26:01:35	Unconfirmed	A*26:43:02	Confirmed	A*26:94	Unconfirmed		
A*26:01:36	Unconfirmed	A*26:45	Confirmed	A*26:95	Unconfirmed		
A*26:01:37	Unconfirmed	A*26:46	Unconfirmed	A*26:96	Unconfirmed		
A*26:01:38	Unconfirmed	A*26:47	Confirmed	A*26:97	Unconfirmed		
A*26:01:39	Unconfirmed	A*26:48	Unconfirmed	A*26:98	Unconfirmed		
A*26:01:41	Confirmed	A*26:49	Confirmed	A*26:99	Unconfirmed		
A*26:02:01	Confirmed	A*26:50	Unconfirmed	A*26:100	Unconfirmed		
A*26:02:02	Unconfirmed	A*26:51	Unconfirmed	A*26:101	Unconfirmed		
A*26:03:01	Confirmed	A*26:52	Confirmed	A*26:102	Unconfirmed		
A*26:04	Confirmed	A*26:53	Unconfirmed	A*26:103	Confirmed		
A*26:05	Confirmed	A*26:54	Unconfirmed	A*26:104	Confirmed		
A*26:06	Confirmed	A*26:55	Unconfirmed	A*26:105	Unconfirmed		
A*26:07:01	Unconfirmed	A*26:56	Unconfirmed	A*26:106	Confirmed		

<sup>1</sup>Allele status “confirmed” or “unconfirmed” as listed on the IMGT/HLA web page 2016-October-14, release 3.26.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

### RESOLUTION IN HOMO- AND HETEROZYGOTES

Results file with resolution in HLA-A\*26 homo- and heterozygotes is available upon request.

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information  
**SPECIFICITY TABLE**

**HLA-A\*26 SSP subtyping**

Specificities and sizes of the PCR products of the 47+1 primer mixes used for HLA-A\*26 SSP subtyping.

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	Amplified HLA-A*26 alleles <sup>3</sup>	Other amplified HLA-A alleles
1 <sup>5</sup>	180 bp	800 bp	*26:01:01:01-26:01:46, 26:03:01, 26:05, 26:07:01-26:08, 26:10-26:28, 26:30-26:39, 26:41-26:43:02, 26:45-26:48, 26:50-26:74, 26:76-26:77, 26:79-26:90, 26:92-26:117, 26:119-26:131, 26:133-26:137, 26:139-26:149	*02:135, 11:116, 11:140, 25:01:01:01-25:05, 25:07-25:35, 25:37-25:42N, 25:44-25:46, 31:24-31:25, 32:26:01-32:26:02, 33:61, 43:01, 66:01:01:01-66:01:03, 66:04-66:09, 66:11-66:15, 66:17-66:20, 66:22-66:24, 66:27N, 66:29-66:31
2 <sup>4</sup>	80 bp	800 bp	*26:01:01:01-26:02:02, 26:04, 26:08-26:18, 26:20, 26:22-26:29, 26:32-26:43:02, 26:45-26:56, 26:58-26:71N, 26:73-26:75, 26:77, 26:79-26:91, 26:93-26:110, 26:112-26:113, 26:115-26:149	*01:51, 02:644, 29:105, 33:13, 33:48, 68:84
3	140 bp	1070 bp	*26:02:01-26:02:02, 26:118, 26:132, 26:138	
4 <sup>6,8</sup>	260 bp	800 bp	*26:03:01, 26:06, 26:21, 26:30, 26:78, 26:92, 26:111	*01:134, 01:229, 02:243:03, 02:591:01, 02:666, 03:09, 03:89:02, 03:108, 03:172, 03:198, 11:06, 11:18, 29:19, 29:48, 30:13, 30:16, 30:44, 30:46, 33:24, 68:05, 68:15, 68:20, 74:06, 74:21
5	180 bp	1070 bp	*26:04, 26:78	
6 <sup>4</sup>	80 bp	1070 bp	*26:05	*68:109, 68:136
7 <sup>7</sup>	150 bp	800 bp	*26:08, 26:28, 26:48, 26:52, 26:67, 26:73, 26:81, 26:86, 26:91, 26:124, 26:146	*25:04, 25:44
8	135 bp	1070 bp	*26:11N, 26:14, 26:18, 26:28, 26:52, 26:73, 26:112, 26:146	*03:01:19, 03:103:02, 25:09, 31:03-31:04, 31:123, 34:03, 34:06, 34:17, 66:22, 74:01:03
9	145 bp	1070 bp	*26:12, 26:18	*02:309, 02:454, 25:28, 25:30, 31:03-31:04, 31:123, 34:06, 66:06, 74:01:03
	190 bp		*26:29, 26:49	*01:01:56, 25:36, 66:10
10 <sup>4</sup>	85 bp 260 bp	1070 bp	*26:07:01-26:07:02 *26:20	*01:83:01-01:83:02, 02:146 *01:01:13, 02:146 <sup>w</sup> , 02:644 <sup>w</sup>
11	145 bp	800 bp	*26:06, 26:19, 26:45	*01:117 <sup>w</sup> , 30:125, 31:03
12 <sup>6</sup>	140 bp	1070 bp	*26:14, 26:18, 26:28, 26:52, 26:73, 26:112, 26:146	*03:01:19, 03:103:02, 25:09, 31:03-31:04, 31:123, 34:03, 34:06, 34:17, 66:22, 74:01:03

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

Lot No.	Fragment Size	Reference Size	Allele	Sequence
	240 bp		*26:16	*01:02, 01:20, 01:188, 01:190, 24:04, 24:109, 24:129, 29:37, 29:56, 30:57, 30:90
13 <sup>4</sup>	110 bp 255 bp	1070 bp	*26:45, 26:106 *26:17	*01:184
14	145 bp	1070 bp	*26:10	*01:88:02, 01:236, 02:38, 02:101:01, 02:154, 02:447, 02:543, 11:119:01-11:119:02, 23:10, 24:10:01-24:10:02, 24:46, 24:210, 24:300, 24:340, 68:61, 68:134
15 <sup>4</sup>	100 bp	<b>800 bp</b>	*26:13, 26:19, 26:33	*01:13, 01:17, 01:176, 03:63, 03:88, 11:01:01:01-11:01:67, 11:01:69-11:01:72, 11:01:74-11:01:75, 11:01:77-11:11, 11:13-11:16, 11:20-11:27, 11:29-11:39, 11:41-11:52Q, 11:54-11:95, 11:97, 11:99N-11:105, 11:107-11:120, 11:122-11:158, 11:160-11:177, 11:179-11:249, 11:251N-11:280, 25:02, 29:66, 30:125, 34:01:01:01-34:06, 34:08, 34:10N-34:17, 66:01:01:01-66:01:03, 66:04, 66:06-66:11, 66:13-66:14, 66:17-66:20, 66:22-66:24, 66:27N, 66:29-66:31, 69:02, <b>C*07:335</b>
16	430 bp	1070 bp	*26:13, 26:19, 26:33	*02:34 <sup>w</sup> , 02:35:01-02:35:03, 02:56:01 <sup>w</sup> -02:56:02 <sup>w</sup> , 02:62 <sup>w</sup> , 02:78, 02:103 <sup>w</sup> , 02:580, 03:242, 23:13, 24:07:01-24:07:02, 24:19, 24:24, 24:112, 24:131, 24:288, 24:290, 24:294Q, 24:339, 24:347:01-24:347:02, 24:387, 34:01:01:01-34:13, 34:15-34:17, 66:01:01:01-66:02, 66:04, 66:06-66:14, 66:16-66:27N, 66:29-66:31, 68:01:01:01-68:02:12, 68:06-68:14, 68:16-68:19, 68:21:01-68:30, 68:32-68:56, 68:58:01-68:89, 68:91-68:108, 68:110-68:177, 69:01:01:01-69:03
17 <sup>4</sup>	105 bp 175 bp	1070 bp	*26:74 *26:09, 26:91	*02:309, 02:454, 03:01:19, 03:103:02, 25:06, 31:03-31:04, 31:123, 34:01:01:01-34:09, 34:12-34:17, 74:01:03
18 <sup>4</sup>	125 bp 205 bp	1070 bp	*26:31 *26:21, 26:115	*01:60, <b>C*06:71, C*07:581</b>
19	190 bp 245 bp	<b>800 bp</b>	*26:40 *26:22	*01:20 <sup>w</sup> , 01:66 <sup>w</sup> , 01:130 <sup>w</sup> , 02:38, 02:101:01, 02:447, 02:543, 66:09
20 <sup>4,6</sup>	60 bp 210 bp	1070 bp	*26:27 *26:23	*01:243 <sup>w</sup> *01:182 <sup>w</sup> , 11:185
21 <sup>4,5</sup>	115 bp	1070 bp	*26:24, 26:99	*02:140, 02:241, 02:684, 31:48, 33:15, 33:31
22 <sup>4,6</sup>	135 bp 205 bp 100 bp 170 bp 220 bp	1070 bp	*26:82 *26:41 *26:25N *26:98 *26:38	<b>C*04:199, C*06:75</b>
23	130 bp	1070 bp	*26:56, 26:82	



101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

Lot No.	Fragment Size(s)	Reference Size	Allele(s)	Gene(s)
24	165 bp		*26:26	
	305 bp	1070 bp	*26:32, 26:70	*01:03:01:01-01:03:01:02, 01:192, 11:26, 11:118, 29:66, 32:62, 33:13, 36:03, 74:10, <b>C*06:72</b>
25 <sup>7</sup>	360 bp	1070 bp	*26:30, 26:65	*02:135, 02:309, 02:454, 03:01:19, 03:103:02, 25:13, 31:04, 31:123, 34:09, 66:02-66:03:01:02, 66:12, 66:16, 66:21, 66:25-66:26Q, 66:28N, 74:01:03
26 <sup>6</sup>	175 bp	1070 bp	*26:01:21, 26:34, 26:73	*66:01:02
27 <sup>4</sup>	125 bp	1070 bp	*26:76	
	150 bp		*26:145N	
	275 bp		*26:35	
28 <sup>4</sup>	90 bp	1070 bp	*26:03:01, 26:06, 26:21, 26:36, 26:78, 26:92, 26:111, 26:146	*01:104, 01:134, 01:229, 02:346, 02:427, 11:06, 25:11, 80:01:01:01 <sup>w</sup>
	265 bp		*26:116	
29	330 bp	1070 bp	*26:37	*24:74:02
	475 bp		*26:104	
30 <sup>4</sup>	120 bp	1070 bp	*26:15, 26:29, 26:56, 26:99	*02:140, 11:91:01, 31:48, 33:15, <b>B*35:108:01, B*44:248, B*53:26, C*12:91</b>
	235 bp		*26:33	
31	210 bp	<b>800 bp</b>	*26:39	*01:140 <sup>w</sup>
32 <sup>4</sup>	90 bp	1070 bp	*26:61	*02:309, 02:454, 03:01:19, 03:103:02, 25:19:01-25:19:02, 25:30, 31:03-31:04, 31:123, 34:02:01, 34:02:03-34:04, 34:06-34:09, 34:13, 34:15, 66:06, 74:01:03
	155 bp		*26:43:01	
	205 bp		*26:21, 26:115	
33 <sup>4,6</sup>	105 bp	1070 bp	*26:46	
	170 bp		*26:98	
	200 bp		*26:53	
34	140 bp	1070 bp	*26:47, 26:127N	*25:08, 66:18
	190 bp		*26:29, 26:49	*01:01:56, 25:36, 66:10
35 <sup>4</sup>	115 bp	1070 bp	*26:48, 26:69, 26:114	*34:01:01:01-34:01:02, 34:05, 34:11-34:12, 34:14, 34:16-34:17, <b>C*04:49, C*07:262, C*07:417, C*07:475</b>
	245 bp		*26:59	
36 <sup>4</sup>	125 bp	1070 bp	*26:54	*02:454, 25:05
	150 bp		*26:127N	
	215 bp		*26:55	
	245 bp	<b>800 bp</b>	*26:50	
37	415 bp		*26:64, 26:66	*68:89
	90 bp	1070 bp	*26:75	*01:205, 11:34
38 <sup>4</sup>	150 bp		*26:145N	
	190 bp		*26:51	*01:168, 11:262
	220 bp	<b>800 bp</b>	*26:63	*24:181
39 <sup>5</sup>	410 bp		*26:62, 26:64, 26:72	*02:609, 23:09, 24:129, 68:89
	90 bp	1070 bp	*26:57	*68:86, <b>B*39:104</b>
40 <sup>4</sup>	150 bp		*26:42	
	255 bp		*26:57	*68:86, <b>B*39:104</b>
	140 bp	1070 bp	*26:60N	

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

Allele	Product Size(s)	Control Size	Allele Specific Information	Internal Control
<b>42</b>	425 bp 460 bp	1070 bp	*26:66 *26:58	*02:81, 02:87, 02:112, 02:124, 02:129, 02:136, 02:571, 23:01:01:01-23:68, 23:70-23:88, 24:02:01:01-24:02:32, 24:02:34-24:03:04, 24:05:01-24:11N, 24:13:01-24:15, 24:17-24:18, 24:20:01:01-24:25, 24:27, 24:29-24:43, 24:45N-24:64, 24:66-24:88, 24:90:01N-24:99, 24:101-24:108, 24:110-24:128, 24:130-24:183N, 24:185N-24:210, 24:212-24:213, 24:215-24:239, 24:242-24:289, 24:291-24:293, 24:295-24:372, 24:374-24:400, 25:01:01:01-25:46, 68:36, <b>B*27:163</b>
<b>43<sup>4</sup></b>	90 bp 175 bp	1070 bp	*26:107N *26:103	*25:18
<b>44<sup>4</sup></b>	105 bp 235 bp	1070 bp	*26:68 *26:130	*25:27:01, 66:14
<b>45</b>	155 bp 275 bp	1070 bp	*26:42, 26:71N *26:104	*11:208N, 68:94N, <b>B*35:173:01N</b>
<b>46</b>	145 bp	1070 bp	*26:18 <sup>w</sup> , 26:28, 26:43:02, 26:112	*31:03 <sup>w</sup> -31:04 <sup>w</sup> , 31:123 <sup>w</sup> , 34:02:02, 34:06 <sup>w</sup> , 74:01:03 <sup>w</sup>
<b>47</b>	145 bp	1070 bp	*26:01:01:03N	
<b>48<sup>9</sup></b>	-	-	<b>Negative Control</b>	

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-A\*26 SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

<sup>4</sup>HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

<sup>5</sup>Primer mixes 1 and 39 have a tendency to giving rise to primer oligomer formation.

<sup>6</sup>Primer mixes 4, 12, 20, 22, 26 and 33 may have tendencies of unspecific amplifications.

<sup>7</sup>Primer mixes 7 and 25 may give rise to a lower yield of HLA-specific PCR product than the other A\*26 primer mixes.

<sup>8</sup>In primer mix 4 the positive control band may be weaker than for other HLA-A\*26 primer mixes.

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

**Lot No.: 6G1**

**Lot-specific information**

<sup>9</sup>Primer mix 48 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 430 base pairs.

‘w’, may be weakly amplified.

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information  
**PRIMER SPECIFICATION**

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec.	180	80	140	260	180	80	150	135	145	85	145	140
PCR product									190	260		240
Length of int.	<b>800</b>	<b>800</b>	1070	<b>800</b>	1070	1070	<b>800</b>	1070	1070	1070	<b>800</b>	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	418	261	418	74	423	261	423	423	423	78	233	98
	5'-Agg 3'	5'-AAC 3'	5'-AgA 3'	5'-C 3'	5'-gCT 3'	5'-AAC 3'	5'-gCT 3'	5'-gCT 3'	5'-gCT 3'	5'-TCT 3'	5'-gCg 3'	5'-CTC 3'
				78						257	243	423
				5'-TCC 3'						5'-Cgg 3'	5'-CCT 3'	5'-gCT 3'
											416	
											5'-gCg 3'	
3'-primer(s) <sup>3</sup>	559	299	517	292	560	299	524	517	527	299	341	299
	5'-CCT 3'	5'-TCg 3'	5'-CgT 3'	5'-gTg 3'	5'-ACA 3'	5'-TCT 3'	5'-CAC 3'	5'-CgC 3'	5'-CCA 3'	5'-TCg 3'	5'-CgT 3'	5'-TCg 3'
	560	308	517				538	519	570		517	517
	5'-ACC 3'	5'-TCT 3'	5'-CgT 3'				5'-CTg 3'	5'-ggA 3'	5'-CCg 3'		5'-CgT 3'	5'-CgC 3'
								524				524
								5'-CAC 3'				5'-CAC 3'
Well No.	1	2	3	4	5	6	7	8	9	10	11	12

Well No.	13	14	15	16	17	18	19	20	21	22	23	24
Length of spec.	110	145	100	430	105	125	190	60	115	100	130	305
PCR product	255				175	205	245	210	135	170	165	
									205	220		
Length of int.	1070	1070	<b>800</b>	1070	1070	1070	<b>800</b>	1070	1070	1070	1070	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	228	453	282	28	423	257	355	392	395	160	652	341
	5'-ATg 3'	5'-AAA 3'	5'-CAg 3'	5'-TCg 3'	5'-gCT 3'	5'-CCC 3'	5'-CCg 3'	5'-CgA 3'	5'-gCA 3'	5'-ACT 3'	5'-CTg 3'	5'-ggA 3'
	346				423	410	542	652	280			
	5'-gTA 3'				5'-gCT 3'	5'-gTT 3'	5'-gAA 3'	5'-CTg 3'	5'-CCC 3'			
										704		
										5'-Tgg 3'		
3'-primer(s) <sup>3</sup>	299	559	341	282	485	341	559	559	559	341	743	362
	5'-TCg 3'	5'-CCg 3'	5'-CgT 3'	5'-gAC 3'	5'-CCg 3'	5'-CgT 3'	5'-CCg 3'	5'-CCg 3'	5'-CCg 3'	5'-CgT 3'	5'-TCC 3'	5'-TCA 3'
	559	559		290	559	589			727	831	746	
	5'-CCg 3'	5'-CCg 3'		5'-gAA 3'	5'-CgT 3'	5'-CTT 3'			5'-CCA 3'	5'-TCC 3'	5'-ggT 3'	
									728		776	
									5'-CCT 3'		5'-CAA 3'	
									746			
									5'-ggT 3'			
Well No.	13	14	15	16	17	18	19	20	21	22	23	24

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

Well No.	25	26	27	28	29	30	31	32	33	34	35	36
Length of spec.	360	175	125	90	330	120	210	90	105	140	115	125
PCR product			150	265	475	235		155	170	190	245	150
			275					205	200			215
Length of int.	1070	1070	1070	1070	1070	1070	<b>800</b>	1070	1070	1070	1070	1070
pos. control <sup>1</sup>												
5'-primer(s) <sup>2</sup>	341	423	106	116	28	98	391	423	401	423	136	423
	5'-ggC <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-gCg <sup>3'</sup>	5'-TCg <sup>3'</sup>	5'-CTA <sup>3'</sup>	5'-ACC <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-gCC <sup>3'</sup>	5'-gCT <sup>3'</sup>
			232	292		652			495		256	
			5'-AgT <sup>3'</sup>	5'-CTC <sup>3'</sup>		5'-CTg <sup>3'</sup>			5'-CAC <sup>3'</sup>		5'-ACT <sup>3'</sup>	
			255						704		270	
			5'-gAg <sup>3'</sup>						5'-Tgg <sup>3'</sup>		5'-AAA <sup>3'</sup>	
3'-primer(s) <sup>3</sup>	418	559	341	341	186	180	559	472	559	518	341	506
	5'-gTC <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CgT <sup>3'</sup>	5'-CgT <sup>3'</sup>	5'-TCC <sup>3'</sup>	5'-TCC <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CgT <sup>3'</sup>	5'-TgT <sup>3'</sup>
		559			334	290		538	831	532		532
		5'-CCT <sup>3'</sup>			5'-gCC <sup>3'</sup>	5'-gAA <sup>3'</sup>		5'-CAA <sup>3'</sup>	5'-TCC <sup>3'</sup>	5'-CTA <sup>3'</sup>		5'-CTA <sup>3'</sup>
						727		589		570		595
						5'-CCA <sup>3'</sup>		5'-CTT <sup>3'</sup>		5'-CCg <sup>3'</sup>		5'-CCA <sup>3'</sup>
						743						
						5'-TCC <sup>3'</sup>						
Well No.	25	26	27	28	29	30	31	32	33	34	35	36

Well No.	37	38	39	40	41	42	43	44	45	46	47
Length of spec.	245	90	220	90	140	425	90	105	155	145	145
PCR product	415	150	410	150		460	175	235	275		
		190		255							
Length of int.	<b>800</b>	1070	<b>800</b>	1070	1070	1070	1070	1070	1070	1070	1070
pos. control <sup>1</sup>											
5'-primer(s) <sup>2</sup>	28	191	28	98	2 <sup>nd</sup> I	28	423	423	98	423	4 <sup>th</sup> I
	5'-TCg <sup>3'</sup>	5'-CgA <sup>3'</sup>	5'-TCg <sup>3'</sup>	5'-CTA <sup>3'</sup>	5'-CCT <sup>3'</sup>	5'-TCg <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-CTA <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-ggA <sup>3'</sup>
	353	232		261							
	5'-CAg <sup>3'</sup>	5'-AgT <sup>3'</sup>		5'-AAC <sup>3'</sup>							
		565									
		5'-gCA <sup>3'</sup>									
3'-primer(s) <sup>3</sup>	265	341	77	208	426	283	470	486	208	517	899
	5'-CCA <sup>3'</sup>	5'-CgT <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-TCC <sup>3'</sup>	5'-TgC <sup>3'</sup>	5'-TCT <sup>3'</sup>	5'-gCg <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CgC <sup>3'</sup>	5'-ACg <sup>3'</sup>
	283	616	265	311		319	559	616	224	538	
	5'-TgC <sup>3'</sup>	5'-CgT <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-ggA <sup>3'</sup>		5'-gCg <sup>3'</sup>	5'-CCC <sup>3'</sup>	5'-CgC <sup>3'</sup>	5'-TCT <sup>3'</sup>	5'-CAg <sup>3'</sup>	
	559		271						334		
	5'-CCg <sup>3'</sup>		5'-CAT <sup>3'</sup>						5'-gCC <sup>3'</sup>		
Well No.	37	38	39	40	41	42	43	44	45	46	47

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

<sup>2</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A*26 SSP subtyping kit <sup>2</sup>																				
				Well																
				1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	201437801	201894302	201437803	201437804	201437805	201437806	201437807	201437808	201437809	201437810	201779111	201437812	201437813	201437814	201437815	201437816
IHCW cell line <sup>1</sup>			A*																	
1	9001	SA	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280	LK707	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*01:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	9009	KAS011	*01:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353	SM	*02:01	*26:03	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
7	9020	QBL	*26:01		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9025	DEU	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026	YAR	*26:01		+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107	LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051	PITOUT	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052	DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004	JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075	DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037	SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282	CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257	32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038	BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059	SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064	AMALA	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056	KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124	IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
24	9035	JBUSH	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049	IBW9	*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285	WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191	CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
28	9320	BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050	MOU	*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021	RSH	*30:01	*68:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+
31	9019	DUCAF	*30:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297	HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098	MT14B	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302	SSTO	*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024	KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-
37	9065	HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099	LZL	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315	CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134	WHONP199	*02:07	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055	H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066	TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057	TEM	*66:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	+	+
45	9239	SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013	SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303	TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

CELL LINE VALIDATION SHEET																					
HLA-A*26 SSP subtyping kit <sup>2</sup>																					
				Prod. No.:	Well																
					17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	
					201437817	201779118	201437819	201437820	201555921	201555922	201437823	201437824	201437825	201779126	201894327	201779128	201779129	201437830	201437831	201779132	
	IHWC cell line <sup>1</sup>		A*																		
1	9001 SA		*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	9280 LK707		*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011 E4181324		*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275 GU373		*30:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	9009 KAS011		*01:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353 SM		*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
7	9020 QBL		*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9007 DEM		*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026 YAR		*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107 LKT3		*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	9051 PITOUT		*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052 DBB		*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004 JESTHOM		*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071 OLGA		*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075 DKB		*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
16	9037 SWEIG007		*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282 CTM3953540		*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
18	9257 32367		*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038 BM16		*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059 SLE005		*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064 AMALA		*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056 KOSE		*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124 IHL		*02:01	*34:01	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
24	9035 JBUSH		*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049 IBW9		*33:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285 WT49		*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191 CH1007		*24:10	*29:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
28	9320 BEL5GB		*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050 MOU		*29:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021 RSH		*30:01	*68:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019 DUCAF		*30:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297 HAG		*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098 MT14B		*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104 DHIF		*31:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302 SSTO		*32:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024 KT17		*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065 HHKB		*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099 LZL		*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315 CML		*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134 WHONP199		*02:07	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055 H0301		*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066 TAB089		*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076 T7526		*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057 TEM		*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239 SHJO		*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
46	9013 SCHU		*03:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045 TUBO		*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303 TER-ND		*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

CELL LINE VALIDATION SHEET																			
HLA-A*26 SSP subtyping kit <sup>2</sup>																			
				Well															
				33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	
				Prod. No.:	201555933	201779134	201779135	201779136	201779137	201894338	201437839	201779140	201437841	201779142	201555943	201894344	201779145	201779146	201779147
IHWC cell line <sup>1</sup>			A*																
1	9001	SA	*24:02	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
2	9280	LK707	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	9011	E4181324	*01:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	9009	KAS011	*01:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	9353	SM	*02:01	*26:03	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	9020	QBL	*26:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	9007	DEM	*31:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	9026	YAR	*26:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	9107	LKT3	*24:02	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
11	9051	PITOUT	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	9052	DBB	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	9004	JESTHOM	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*31:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	9075	DKB	*24:02	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
16	9037	SWEIG007	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
17	9282	CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18	9257	32367	*33:03	*74:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
19	9038	BM16	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
20	9059	SLE005	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	9064	AMALA	*02:17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
22	9056	KOSE	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
23	9124	IHL	*02:01	*34:01	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-
24	9035	JBUSH	*32:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
25	9049	IBW9	*33:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
26	9285	WT49	*02:05	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
27	9191	CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
28	9320	BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
29	9050	MOU	*29:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
30	9021	RSH	*30:01	*68:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
31	9019	DUCAF	*30:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
32	9297	HAG	*02:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
33	9098	MT14B	*31:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
34	9104	DHIF	*31:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
35	9302	SSTO	*32:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
36	9024	KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
37	9065	HHKB	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
38	9099	LZL	*02:17	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
39	9315	CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
40	9134	WHONP199	*02:07	*30:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
41	9055	H0301	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
42	9066	TAB089	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
43	9076	T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
44	9057	TEM	*66:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239	SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
46	9013	SCHU	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
48	9303	TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



101.424-12 – including *Taq* polymerase, IFU-01  
 101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
 “Instructions for Use” (IFU)

Lot No.: **6G1**

**Lot-specific information**

<sup>1</sup>The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

<sup>2</sup>The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

No DNAs carrying the alleles to be amplified by primer solutions 8 to 11, 13, 18 to 23, 26, 27, 29 to 31, 33, 34, 36 to 41 and 43 to 47 were available. The specificities of the primers in primer solutions 8 to 11, 18, 19, 21, 22, 33, 34, 36, 37, 39, 44 and 46 were tested by separately adding one, two or three additional 5'-primers, respectively one or two additional 3'-primers. In primer solutions 23, 26, 29, 30, 40, 41, 43 and 45 it was only possible to test the 5'-primers, the 3'-primers were not possible to test. In primer solutions 13, 20, 27, 31, 38 and 47 it was only possible to test the 3'-primers, the 5'-primers were not possible to test. In primer solutions 1, 3, 8, 16, 18, 21, 32, 34, 36, 37, 39, 42 and 44 one, two or three of the 3'-primers were not possible to test.

In primer solutions 4, 10, 11, 18, 19, 21, 22, 28, 33, 35 and 37 one or two of the 5'-primers were not possible to test. Additional primers in primer solutions 7, 12 and 17 were tested by separately adding one or more additional 5'-primers, respectively one or more additional 3'-primers.

101.424-12 – including *Taq* polymerase, IFU-01

101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

101.424-12 – including *Taq* polymerase, IFU-01  
101.424-12u – without *Taq* polymerase, IFU-02

Visit [www.olerup.com](http://www.olerup.com) for  
“Instructions for Use” (IFU)

Lot No.: **6G1**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**Olerup SSP AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

**Tel:** +46-8-717 88 27

**Fax:** +46-8-717 88 18

**E-mail:** [olerup-se@caredx.com](mailto:olerup-se@caredx.com)

**Web page:** <http://www.olerup.com>

**Distributed by:**

**Olerup GmbH**, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

**Tel:** +43-1-710 15 00

**Fax:** +43-1-710 15 00 10

**E-mail:** [olerup-at@caredx.com](mailto:olerup-at@caredx.com)

**Web page:** <http://www.olerup.com>

**Olerup Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-OLERUP1

**Fax:** 610-344-7989

**E-mail:** [olerup-us@caredx.com](mailto:olerup-us@caredx.com)

**Web page:** <http://www.olerup.com>

For information on *Olerup* distributors worldwide, contact **Olerup GmbH**.